BB
PRTA icon

BB Biotech’s Prothena Corp PRTA Stock Holding History

BB Biotech’s Portfolio PRTA Stock Details PRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-400,000
Closed -$14.7M – 33
2018
Q1 		$14.7M Buy
400,000
+50,000
+14% +$1.82M 0.41% 28
2017
Q4 		$13.1M Hold
350,000
– – 0.37% 28
2017
Q3 		$22.7M Hold
350,000
– – 0.63% 24
2017
Q2 		$18.9M Hold
350,000
– – 0.58% 25
2017
Q1 		$19.5M Hold
350,000
– – 0.64% 25
2016
Q4 		$17.2M Hold
350,000
– – 0.64% 22
2016
Q3 		$21M Hold
350,000
– – 0.74% 21
2016
Q2 		$12.2M Hold
350,000
– – 0.48% 25
2016
Q1 		$14.4M Buy
350,000
+30,000
+9% +$1.17M 0.57% 23
2015
Q4 		$21.8M Hold
320,000
– – 0.61% 24
2015
Q3 		$14.5M Buy
+320,000
New +$18.6M 0.46% 26

Other funds holding PRTA

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech's PRTA Position: Q2 2018 in Review

BB Biotech sold out of Prothena Corp (PRTA) in Q2 2018, closing a stake of 400,000 shares — an estimated $14.7M sold.

BB Biotech first reported a position in PRTA in Q3 2015 and held it in 11 quarters. The position peaked at $22.7M in Q3 2017. 125 funds tracked by Wall St. Rank hold PRTA as of Q2 2018.

  • BB Biotech reported no remaining Prothena Corp position as of Q2 2018 after selling out during the quarter.
  • BB Biotech sold 400,000 Prothena Corp shares in Q2 2018, an estimated $14.7M.
  • BB Biotech first reported a position in Prothena Corp in Q3 2015 and held it in 11 quarters.
  • BB Biotech's Prothena Corp position peaked at $22.7M in Q3 2017.
  • 125 funds tracked by Wall St. Rank held Prothena Corp as of Q2 2018.

Based on BB Biotech's 13F filing for Q2 2018, filed 9 Aug 2018.